TAS-120 clinical trials

Study of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement

This study looks at a new drug called futibatinib (also known as TAS-120) for people with advanced bile duct cancer (cholangiocarcinoma). It focuses on patients whose cancer has a specific gene change (FGFR2 fusion or rearrangement) and who have already had standard treatments. The study aims to confirm the drug's benefits at one dose and check a different dose.